Growth Metrics

Novavax (NVAX) Other Non-Current Liabilities (2016 - 2025)

Novavax has reported Other Non-Current Liabilities over the past 16 years, most recently at $239.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $239.1 million for Q4 2025, down 33.52% from a year ago — trailing twelve months through Dec 2025 was $239.1 million (down 33.52% YoY), and the annual figure for FY2025 was $239.1 million, down 33.52%.
  • Other Non-Current Liabilities for Q4 2025 was $239.1 million at Novavax, down from $263.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for NVAX hit a ceiling of $359.6 million in Q4 2024 and a floor of $20.6 million in Q2 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $67.9 million (2022), compared with a mean of $151.4 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 62.16% in 2023 and later skyrocketed 985.46% in 2024.
  • Novavax's Other Non-Current Liabilities stood at $42.1 million in 2021, then surged by 32.23% to $55.7 million in 2022, then plummeted by 40.52% to $33.1 million in 2023, then skyrocketed by 985.46% to $359.6 million in 2024, then crashed by 33.52% to $239.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $239.1 million (Q4 2025), $263.5 million (Q3 2025), and $287.6 million (Q2 2025) per Business Quant data.